Loading company…
Boulder-based biopharmaceutical company developing precision cancer medicines, including tumor-agnostic therapies.
OnKure, Inc. discovers and develops precision medicines for cancer, with a focus on tumor-agnostic therapies that can work across tumor types. Its listed revenue streams include milestone payments from development phases and royalties from commercialized therapies. Founded in 2011 in Boulder, US, by Anthony Piscopio and Xuedong Liu, the company raised USD 53.78 million in a Series C round on March 24, 2023, led by Surveyor Capital with returning investors including Acorn Bioventures and BlackRock. Anthony Piscopio is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in